False synergy between vancomycin and β-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods

Clinical Microbiology and Infection

Volumn 10, Issue 4, 2004, Pages 342-345

  Goldstein, F W ^a   Atoui, R ^a   Ali, A Ben ^a   Nguyen, J C ^a   Ly, A ^a   Kitzis, M D ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

GISA; Glycopeptides; Staphylococcus aureus; Susceptibility testing; lactams

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; SODIUM CHLORIDE; TEICOPLANIN; VANCOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; INCUBATION TIME; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 1942440514     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1198-743X.2004.00856.x     Document Type: Article

References (11)

1. Mainardi JL, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995; 171: 1646-1650.
2. Quincampoix JC, Carbonne A, Loyer D et al. Follow-up of a nosocomial outbreak of methicillin-resistant strains of Staphylococcus aureus (MRSA) with decreased susceptibility to teicoplanin (DST) [abstract C167]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial agents and Chemotherapy. Toronto, Canada, Washington DC. American Society for Microbiology 1997.
3. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new-model of antibiotic resistance. Lancet Inf Dis 2001; 1: 147-155.
4. Anonymous. Vancomycin-resistant Staphylococcus aureus-Pennsylvania 2002. Morb Mortal Wkly Rep. 2002; 51: 902.
5. Goldstein F, Kitzis MD. Vancomycin resistant S. aureus: no apocalypse now. Clin Microbiol Infect 2003; 9: 761-765.
6. Trad S, Ben Ali A, Garrouste M et al. Pneumopathies à S. aureus de sensibilité intermédiaire aux glycopeptides (GISA): la vancomycine (Vanco) reste le traitement de reference [abstract 291/P2]. In: Program and abstracts of 22eme Réunion Interdisciplinaire de Chiomthérapie Anti-Infectieuse. Paris, France. Association pour l'Organisation des Réunions Interdisciplinaires de Chimiothérapie Anti-infectieuse 2002.
7. Aritaka N, Hanaki H, Cui L, Hiramatsu K. Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother 2001; 45: 1292-1294.
8. Guerin F, Buu-Hoï A, Mainardi JL et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a parisian hospital. J Clin Microbiol 2000; 38: 2985-2988.
9. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Inf Dis 1999; 29: 760-767.
10. Cui L, Ma X, Sato K et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41: 5-14.
11. Mokhbat J, Acar JF, Goldstein FW. Synergistic effect of imipenem plus teicoplanin against methicillin-resistant, teicoplanin-resistant, coagulase-negative Staphylococci [abstract 125]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, Washington DC. American Society for Microbiology 1991.